Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02734953 · ClinicalTrials.gov registry record · Phase 2

Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH

A Phase 2 study, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).

Completed
Registry status
Phase 2
Development phase
10
Enrollment target

NCT02734953 is a Phase 2 study that has completed, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02734953, a Phase 2 study, has completed, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target

Study Summary

Pulmonary hypertension is characterized by an increase in the pressures in the blood supply to the lungs greater than a mean pressure of 25mmHg and a concomitant increase in overall pulmonary vascular resistance (PVR). In patients who have remodeling of their pulmonary vasculature, PVR will increase with exercise instead of decreasing as it would in normal patients. Based on published evidence, the investigators intend to investigate the effects of inhaled nitric oxide (iNO) on patients undergoing standard exercise techniques who have separately and previously had an implanted pulmonary artery monitoring device (CardioMems by St Jude Medical, Inc.) placed.

Interventions

  • DRUG Nitric Oxide

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2016-04
Est. Completion 2016-12
Phase Phase 2

What the Registry Record Tells You About NCT02734953

The ClinicalTrials.gov registry entry for NCT02734953 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Nitric Oxide is the first listed.

NCT02734953 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02734953 about?

NCT02734953 is a clinical study titled "Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH". Pulmonary hypertension is characterized by an increase in the pressures in the blood supply to the lungs greater than a mean pressure of 25mmHg and a concomitant increase in overall pulmonary vascular resistance (PVR). In patients who have remodeling of their pulmonary vasculature, PVR will increase...

What is the current status of trial NCT02734953?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2016-04. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02734953?

The interventions under investigation include: Nitric Oxide (DRUG).

Who is sponsoring clinical trial NCT02734953?

This trial is sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.